Our previous study showed that the US-FDA-approved drug regorafenib, which is used for the treatment of HCC and CRC, could stabilize PSAT1 by directly binding to it.24 Since the interaction of PSAT1 and p53 is critical for the activation of mitochondrial function, we inferred that AOA might enhance the sensitivity of cancer cells to regorafenib. The gene discussed is PSAT1; the disease is cancer.